Nasdaq Moves to Delist Moleculin; No Compliance Period Available
MBRX has more than doubled off its 52-week low of $0.161 on light trading volume (0.3× avg).
Summary
Nasdaq issued a Staff Determination Letter on September 15, 2026, finding Moleculin non-compliant with the minimum bid price rule. The company is ineligible for a compliance period due to its December 2025 reverse split and will request a hearing to stay delisting.
Key Events · Legal and Risk Events · MBRX
-
Nasdaq Staff Determination Letter Received
On September 15, 2026, Nasdaq notified Moleculin that its stock has traded below $1.00 for 30 consecutive business days (July 31 through September 11, 2026), violating the minimum bid price requirement.
-
Ineligible for Compliance Period
Because Moleculin effected a 1-for-25 reverse stock split on December 1, 2025, Nasdaq Rule 5810(c)(3)(A)(iv) makes the company ineligible for the standard 180-day compliance period.
-
Hearing Request to Stay Delisting
Moleculin intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting action pending the Panel's decision. There is no assurance the request will be granted.
-
Escalation from Prior Warnings
The August 13, 2026 10-Q warned of Nasdaq delisting risk with no compliance period; this 8-K confirms the formal Staff Determination Letter and the specific ineligibility reason.
Analysis · MBRX · Life Sciences
Nasdaq has formally determined that Moleculin is not in compliance with the minimum bid price requirement. Because the company completed a 1-for-25 reverse stock split in December 2025, it is ineligible for the standard 180-day compliance period. The company will request a hearing before the Nasdaq Hearings Panel, which stays any delisting action pending the Panel's decision. This is a critical escalation from the going-concern and delisting warnings in the August 10-Q, and the stock now trades at $0.7671, well below the $1.00 minimum.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 49.5% of the 190 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.16 to $15.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.